The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy

World Journal of Urology

Volumn 32, Issue 2, 2014, Pages 323-328

  Bañez, Lionel L ^a   Albisinni, Simone ^b   Freedland, Stephen J ^a,c   Tubaro, Andrea ^b   De Nunzio, Cosimo ^b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Area under the ROC curve; Obesity; Prostate biopsy; Prostate cancer screening; Prostate specific antigen; Sensitivity and specificity

Indexed keywords

KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 3, HUMAN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; BODY MASS; COHORT ANALYSIS; HUMAN; IMAGE GUIDED BIOPSY; MALE; MIDDLE AGED; OBESITY; PATHOLOGY; PREDICTIVE VALUE; PROSTATE; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; AREA UNDER CURVE; BODY MASS INDEX; COHORT STUDIES; HUMANS; IMAGE-GUIDED BIOPSY; KALLIKREINS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84897096563     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0919-9     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1): 10-29. doi: 10. 3322/caac. 20138.
2. Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F (2011) Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol 60(1): 1-15. doi: 10. 1016/j. eururo. 2011. 03. 047.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90. doi: 10. 3322/caac. 20107.
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348(17): 1625-1638. doi: 10. 1056/NEJMoa021423.
5. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ (2001) Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10(4): 345-353.
6. Buschemeyer WC 3rd, Freedland SJ (2007) Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 52(2): 331-343. doi: 10. 1016/j. eururo. 2007. 04. 069.
7. Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, Epstein JI, Partin AW (2005) Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol 174 (5): 1798-1801; discussion 1801. doi: 10. 1097/01. ju. 0000177077. 53037. 72.
8. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ (2007) Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298(19): 2275-2280. doi: 10. 1001/jama. 298. 19. 2275.
9. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, Higgins B, Lynch S, Rozanski T, Troyer D, Thompson I (2005) The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103(5): 1092-1095. doi: 10. 1002/cncr. 20856.
10. Barqawi AB, Golden BK, O'Donnell C, Brawer MK, Crawford ED (2005) Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 65(4): 708-712. doi: 10. 1016/j. urology. 2004. 10. 074.
11. Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR, Wener M (2007) Obesity is negatively associated with prostate-specific antigen in US men, 2001-2004. Cancer Epidemiol Biomarkers Prev 16(1): 70-76. doi: 10. 1158/1055-9965. EPI-06-0588.
12. Fowke JH, Motley SS, Cookson MS, Concepcion R, Chang SS, Wills ML, Smith JA Jr (2007) The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 10(2): 137-142. doi: 10. 1038/sj. pcan. 4500924.
13. Grubb RL 3rd, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok PC, Berg CD, Crawford ED, Church TR, Andriole GL Jr (2009) Serum prostate-specific antigen hemodilution among obese men undergoing screening in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 18(3): 748-751. doi: 10. 1158/1055-9965. EPI-08-0938.
14. Beebe-Dimmer JL, Faerber GJ, Morgenstern H, Werny D, Wojno K, Halstead-Nussloch B, Cooney KA (2008) Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study. Urology 71(4): 554-560. doi: 10. 1016/j. urology. 2007. 11. 049.
15. Chang IH, Ahn SH, Han JH, Kim TH, Kim YS, Myung SC (2009) The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration. J Urol 181(2): 567-572; discussion 572-563. doi: 10. 1016/j. juro. 2008. 10. 030.
16. Lopez Fontana C, Maselli ME, Perez Elizalde R, Di Milta N, Corica Alberto P, Lopez Laur JD (2011) Obesity modifies prostatic specific antigen in men over 45 years. Arch Esp Urol 64(1): 35-42.
17. Ando R, Nagaya T, Hashimoto Y, Suzuki S, Itoh Y, Umemoto Y, Ikeda N, Tozawa K, Kohri K, Tokudome S (2008) Inverse relationship between obesity and serum prostate-specific antigen level in healthy Japanese men: a hospital-based cross-sectional survey, 2004-2006. Urology 72(3): 561-565. doi: 10. 1016/j. urology. 2008. 04. 008.
18. Kubota Y, Seike K, Maeda S, Shinohara Y, Iwata M, Sugimoto N (2011) Relationship between prostate-specific antigen and obesity in prostate cancer screening: analysis of a large cohort in Japan. Int J Urol 18(1): 72-75. doi: 10. 1111/j. 1442-2042. 2010. 02667. x.
19. De Nunzio C, Trucchi A, Miano R, Stoppacciaro A, Fattahi H, Cicione A, Tubaro A (2009) The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. J Urol 181(3): 1069-1074; discussion 1074-1065. doi: 10. 1016/j. juro. 2008. 10. 163.
20. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9): 1228-1242.
21. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13): 1310-1319. doi: 10. 1056/NEJMoa0810696.
22. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13): 1320-1328. doi: 10. 1056/NEJMoa0810084.
23. Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, Sarma AV (2011) The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection. Cancer Epidemiol Biomarkers Prev 20(3): 501-508. doi: 10. 1158/1055-9965. EPI-10-1006.
24. Chavarro JE, Toth TL, Wright DL, Meeker JD, Hauser R (2010) Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril 93(7): 2222-2231. doi: 10. 1016/j. fertnstert. 2009. 01. 100.
25. De Nunzio C, Miano R, Trucchi A, Finazzi Agro E, Tubaro A (2008) Finasteride for prostatic disease: an updated and comprehensive review. Expert Opin Drug Metab Toxicol 4(12): 1561-1568. doi: 10. 1517/17425250802587058.
26. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr (2006) Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98(16): 1128-1133. doi: 10. 1093/jnci/djj307.
27. Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC, Jr., Kane CJ, Amling CL, Moul JW, Freedland SJ (2009) Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol 182 (2): 491-496; discussion 496-498. doi: 10. 1016/j. juro. 2009. 04. 007.
28. Loeb S, Carter HB, Schaeffer EM, Ferrucci L, Kettermann A, Metter EJ (2009) Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol 182(6): 2646-2651. doi: 10. 1016/j. juro. 2009. 08. 041.
29. Rundle A, Neugut AI (2008) Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 68(4): 373-380. doi: 10. 1002/pros. 20704.
30. Liang Y, Ankerst DP, Sanchez M, Leach RJ, Thompson IM (2010) Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology 76 (5): 1268 e1261-e1266. doi: 10. 1016/j. urology. 2010. 04. 060.